Search academic texts

Information × Registration Number 0219U100901, 0114U002217 , R & D reports Title The study of the efficacy of structurally-modifying and hypouricemic drugs in the treatment of patients with osteoarthritis and hyperuricemia syndrome popup.stage_title Head Kovalenko Volodimir M., Доктор медичних наук Registration Date 26-03-2019 Organization Shupyk National Medical Academy of Postgraduate Education popup.description2 There have been determined the relationships between the presence of severe osteoarthritis and hyperuricemia according to the VAS, WOMAC scores and Leken’s functional index, and the affection of a greater number of joints (predominantly polyostearthritis in the absence of monoarthrosis) and also a higher X-ray stage.There was studied an influence of chondroitin sulfate and diacerein on the inflammatory process (IL-1, TNF-α, CRP, ESR, inflammatory index score), anti-inflammatory process (IGF-1, TGF-β), free radicals involved in cartilage degeneration (NO). For the first time, the pleiotropic effect of diacerein on purine metabolism (decreased uric acid) was detected. Also, the indications and efficacy of potassium-sodium-hydrocitrate complex, namely, its positive effect on purine metabolism and arterial pressure, were determined for the first time. There were developed and implemented into practice the ways of determining uric acid level, CRP, bone mineral density in order to estimate and predict the course of osteoarthrosis with concomitant hyperuricemia and for the differentiation structurally-modifying and hypouricemic drug therapy. This significantly contributes to restoring the function of the diseased joints and improving the quality of life in patients with osteoarthritis and hyperuricemia due to the high anti-inflammatory and structural-modifying effect of chondroprotective drugs and the reduction in serum uric acid levels. Product Description popup.authors popup.nrat_date 2020-04-02 Close